Aims. To characterize hypogonadism in male persons with diabetes mellitus. Patients and Methods. 184 consecutive male persons with diabetes were studied. Besides the usual care, total testosterone (TT), estradiol (E2), FSH, and LH were measured in the last appointment and in 40 patients, also in the next two appointments. Statistical analysis compared groups and explored factors for TT and LH levels. Results. TT levels were stable and highly correlated (r > 0.750, ) over a 6–12-month period. 20% of the patients presented secondary hypogonadism (SH) and 18% presented primary hypogonadism (PH). SH was inversely related to HbA1 (partial r (rp) = 0.229, ), while PH was directly related to age (r = 0.356, ). TT levels were reduced independently by metformin (364 ± 160 vs. 431 ± 242 ng/dL, t = 2.241, ) and statins (359 ± 156 vs. 424 ± 230 ng/dl, t = 2.224, ). TT levels were inversely related to microvascular disease (rp = −0.169, ). Discussion. TT levels were stable over time and hypogonadism was common. SH, generally clinically, is related to the diabetic state, while PH, generally subclinically, is an age-dependent process unrelated to diabetes. Low TT levels were related to older age, poor metabolic control, metformin and statins use, and microvascular disease.
9 December 2016 in GE - Portuguese Journal of Gastroenterology
Sarcoidosis involving the digestive tract is very rare and requires a strict differential diagnosis with other systemic granulomatous diseases. We present a case of multisystemic granulomatosis involving the stomach and colon, causing initial digestive symptoms. Pulmonary nodules, pleural effusion, ascites, hepatomegaly, splenomegaly, and mesenteric as well as retroperitoneal and axillary lymphadenopathy were subsequently identified. The reticulo-endothelial expression, the hypercalcemia and, above all, a rapid and complete resolution after corticosteroids supported the hypothesis of sarcoidosis involving the digestive tract. A brief review of digestive tract involvement in sarcoidosis and of the distinctive features of sarcoidosis with gastrointestinal involvement and Crohn's disease with a rare form of pleuro-pulmonary involvement is presented.
Key Clinical Message: Intratumoral or intraperitoneal hemorrhage is a recognized complication of liver adenomatosis. We report a case of multifocal massive liver adenomatosis presenting as chronic iron deficiency anemia. Clinicians’ awareness about this atypical presentation not highlighted in the literature is important to allow timely diagnosis and surgical intervention to prevent fatal complications.
8 March 2021 in International Journal of Hypertension
Background. Controversies exist about the effect of renin-angiotensin system inhibitors (RASi) on coronavirus disease 2019 (COVID-19) outcome. The inhospital use of RASi and its effect on inflammatory sate are still poorly studied during the COVID-19 pandemic. Objectives. We aimed to compare the impact of previous and inhospital RASi exposure on the outcome and inflammatory response of COVID-19 patients. Methods. Single-centre, ambispective analysis of hospitalized adult COVID-19 patients at Hospital de Santa Maria, Lisbon, between March and August 2020 was performed. We excluded asymptomatic patients and those admitted due to another disease. The primary outcome was inhospital all-cause mortality. Illness severity was assessed based on the development of acute respiratory distress syndrome/acute lung injury (ARDS/ALI), intensive care unit (ICU) admission, and need for invasive mechanical ventilation (IMV). We used C-reactive protein (CRP), ferritin, and interleukin 6 (IL-6) as surrogate markers of the inflammatory response. Results. From a total of 432 patients, 279 were selected, among whom 133 (47.7%) were receiving a RASi. Chronic treatment with RASi was not associated with the risk of death (OR 1.24, 95% CI 0.66–2.31, ), ARDS/ALI development (OR 1.12, 95% CI 0.67–1.86, ), ICU admission (OR 1.11, 95% CI 0.67–1.84, p = 0.686), and IMV need (OR 1.03, 95% CI 0.58–1.84, ) in a univariable and multivariable analysis. Inhospital RASi withdrawing was associated with the risk of death (OR 4.38, 95% CI 1.11–17.21, ) and ARDS/ALI development (OR 4.33, 95% CI 1.49–12.6, ), the latter remaining significant after adjustment. Previous exposure to RASi was associated with lower CRP levels at admission ( ). IL-6 levels were significantly higher in those patients whose RASi were stopped ( ). Conclusion. Previous and inhospital exposure to RASi was not associated with mortality nor severity of COVID-19. This study supports current guidance on RASi management during the COVID-19 pandemic.
SARS-CoV-2 has emerged as a novel human pathogen, causing clinical signs, from fever to pneumonia – COVID-19 – but may remain mild or even asymptomatic. To understand the continuing spread of the virus, to detect those who are and were infected, and to follow the immune response longitudinally, reliable and robust assays for SARS-CoV-2 detection and immunological monitoring are needed and have been setup around the world. We quantified immunoglobulin M (IgM), IgG and IgA antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) or the Spike (S) protein over a period of five months following COVID-19 disease onset or in previously SARS-CoV-2 PCR-positive volunteers. We report the detailed setup to monitor the humoral immune response from over 300 COVID-19 hospital patients and healthcare workers, 2500 University staff and 187 post-COVID19 volunteers, and assessing titres for IgM, IgG and IgA. Anti-SARS-CoV-2 antibody responses followed a classic pattern with a rapid increase within the first three weeks after symptoms. Although titres reduce from approximately four weeks, the ability to detect SARS-CoV-2 antibodies remained robust for five months in a large proportion of previously virus-positive screened subjects. Our work provides detailed information for the assays used, facilitating further and longitudinal analysis of protective immunity to SARS-CoV-2. Moreover, it highlights a continued level of circulating neutralising antibodies in most people with confirmed SARS-CoV-2, at least up to five months after infection.
Introdução: As informações relativas às características clínicas e demográficas dos doentes portugueses hospitalizados com COVID-19 são limitadas. Material e Métodos: Estudo ambispetivo dos doentes internados com COVID-19 num hospital terciário português entre março e agosto de 2020. Foram excluídos os doentes assintomáticos, mulheres grávidas e os internados por causas sociais. Resultados: Dos 432 doentes internados, foram incluídos 279. A idade mediana foi de 69 anos, 57% do sexo masculino. As comorbilidades mais frequentes foram a hipertensão arterial (66,3%), dislipidémia (33,3%), diabetes (27,1%) e doença cardiovascular (DCV) (26,5%). A sintomatologia mais frequente à admissão foi febre (74,4%), tosse (67,0%) e dispneia (59,9%). As alterações laboratoriais mais frequentes foram níveis elevados de ferritina (86,3%), proteína c-reativa (74,8%) e d-dímeros (73,9%). A taxa de mortalidade foi 17,3%, 32,3% dos doentes desenvolveram síndrome de dificuldade respiratória aguda, 31,9% foram admitidos numa unidade de cuidados intensivos e 20,8% foram ventilados mecanicamente. Na análise multivariável, a idade (OR 1,04, 95% CI 1,01–1,09, p=0,023), DCV (OR 2,68, 95% CI 1,21–5,93, p=0,015) e linfopenia <0,5x109/L (OR 6,61, 95% CI 2,23–19,62, p=0,001) identificaram-se como os principais fatores de risco de mortalidade intra-hospitalar. Discussão: Os nossos dados demográficos e desfechos clínicos equiparam-se aos estudos publicados até à data. Em comparação com os estudos em populações europeias, relatamos uma menor taxa de mortalidade intra-hospitalar, o que poderá refletir um melhor controlo da primeira vaga da pandemia no nosso país. Conclusão: Este estudo fornece informação acerca das características clínicas dos doentes com COVID-19 hospitalizados em Portugal.